AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.790

+0.1701.09%

Volume:570.52K

Turnover:8.91M

Market Cap:5.35B

PE:-536.76

High:15.960

Open:15.500

Low:15.195

Close:15.620

52wk High:19.070

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.14

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.029

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.87

PE(LYR):-536.76

Loading ...

Overview Company News Filings

Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration

Simply Wall St.

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy

ASX Biggest Losers

MT Newswires Live

ASX Growth Leaders With High Insider Ownership April 2026

Simply Wall St.

How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

Plus Therapeutics starts REYOBIQ manufacturing technology transfer with SpectronRx under MSA

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

MT Newswires Live

BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible Bonds

Telix Pharmaceuticals Ltd - Telix Announces Settlement of US$600M Convertible Bonds

THOMSON REUTERS

Telix Pharmaceuticals Ltd - New Bonds Expected to Be Listed on Sgx-St on April 23, 2026

THOMSON REUTERS

Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch

Simply Wall St.

Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows

MT Newswires Live

NuWays reiterates Eckert & Ziegler buy rating, sets EUR 23 target price

Telix Pharmaceuticals Says JPMorgan Increases Stake

MT Newswires Live

Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial

MT Newswires Live

Stock Track | Telix Pharmaceuticals Plummets 5.11% Intraday Following $600 Million Convertible Bond Offering

Telix Doses First Patient in Phase 3 Ipax-Bright Trial of Tlx101-Tx for Recurrent Glioblastoma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/TLX.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.79,"timestamp":1787533416818,"preClose":15.62,"halted":0,"volume":570516,"delay":0,"changeRate":0.010883482714468627,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.029417259426767758,"marketStatus":"Trading","change":0.17,"latestTime":"08-24 11:03:36 AEST","open":15.5,"high":15.96,"low":15.195,"amount":8914789,"amplitude":0.048976,"askPrice":15.8,"askSize":47,"bidPrice":15.79,"bidSize":48,"shortable":3,"etf":0,"ttmEps":-0.029417259426767758,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":15.62,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":1.140306,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.62,"auctionPrice":15.5,"auctionVolume":23842,"auctionTime":1787529541219,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529541219}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029417,"volumeRatio":1.140306,"shares":338721355,"dividePrice":0,"high":15.96,"amplitude":0.048976,"preClose":15.62,"low":15.195,"week52Low":8.26,"pbRate":"7.87","psRate":"4.31","week52High":19.07,"institutionHeld":0,"latestPrice":15.79,"committee":0.010526,"eps":-0.029417259426767758,"divideRate":0,"volume":570516,"delay":0,"ttmEps":-0.029417259426767758,"open":15.5,"prevYearClose":11.2,"prevWeekClose":15.62,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.45,"twentyDayClose":14.28,"sixtyDayClose":13.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631280524","title":"Telix Phase 2 OPTIMAL-PSMA trial shows favorable dosimetry for TLX597-Tx radioligand therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2631280524","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631280524?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:17","pubTimestamp":1777497427,"startTime":"0","endTime":"0","summary":"Telix presented initial dosimetry results from randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx at IPCS 2026, outlining a safety profile that could support more intensive dosing.Data indicated reduced radiation exposure to salivary glands and kidneys, a finding that could lower treatment-limiting side effects and improve tolerability.Telix framed results as supportive of moving TLX597-Tx into earlier-stage metastatic hormone-sensitive prostate cancer, where quality-of-life constraints can limit use of existing radioligand therapies.Company plans to initiate OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive metastatic prostate cancer, to extend evaluation beyond advanced disease.Program sits alongside TLX591-Tx, Telix’s Phase 3 ProstACT Global candidate in mCRPC, positioning portfolio for stage-specific prostate cancer treatment strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6t2JZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527403","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527403","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631527403?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:09","pubTimestamp":1777496942,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing plans to showcase OPTIMAL-PSMA 2 data on its TLX597-Tx candidate, alongside upcoming TLX591-Tx trial results and a new collaboration with Regeneron Pharmaceuticals.\nSee our latest analysis for Telix Pharmaceuticals.\nThese clinical updates and the Regeneron partnership arrive during a period of strong share price momentum, with Telix recording a 15.03% 1 month share price return and a 35.38% 3 month share price return,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516078","title":"Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516078?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:01","pubTimestamp":1777464060,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals got a quiet reception from Wall Street on Wednesday despite a first-quarter earnings beat, as investors remain fixated on the release of key data later this year.The Tarrytown, N.Y.-based drugmaker posted adjusted earnings of $9.47 a share, handily beating the $8.89 Wall Street had anticipated. Revenue ticked higher to $3.61 billion from $3.03 billion last year, surpassing analysts' calls for $3.48 billion.Sales of Dupixent, the blockbuster anti-inflammatory drug co-developed with Sanofi, rose 33% to $4.9 billion in the first quarter. Dupixent recently was approved by both U.S. and European regulators for young children with chronic spontaneous urticaria, and was separately approved by the Food and Drug Administration to treat allergic fungal rhinosinusitis.Other products didn't fare as well. Sales of the standard formulation of Eylea, a prescription ophthalmologic medicine, fell 10% to $941 million. However, sales of higher-dose Eylea HD surged 52% to $468 mi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0058720904.USD","LU2089984988.USD","LU2106854487.HKD","LU2362540622.SGD","BK4585","LU1917777945.USD","REGN","TLX.AU","LU0109394709.USD","IE00BFXG1179.USD","LU2362541273.HKD","LU0320765992.SGD","LU0053666078.USD","BK7067","LU2023250504.SGD","LU2468319806.SGD","LU0114720955.EUR","BK4007","BK4588","LU0889565916.HKD","LU1974910355.USD","LU2237438978.USD","BK4139","LU0823434583.USD","LU0882574055.USD","LU0823434740.USD","SNY","LU0823416689.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630469683","title":"Telix to host webinar on next-generation PSMA-targeted prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2630469683","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630469683?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:07","pubTimestamp":1777331262,"startTime":"0","endTime":"0","summary":"Telix will host an educational webinar on PSMA-targeted radionuclide therapy on April 30, 2026 at 9:30 a.m. AEST.Session will also run on April 29, 2026 at 7:30 p.m. EDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL8LZqpR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630652359","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2630652359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630652359?lang=en_us&edition=fundamental","pubTime":"2026-04-27 11:59","pubTimestamp":1777262349,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech : -3%, AU$42.79NexGen Energy : -3%, AU$17.26Telix Pharmaceuticals : -2%, AU$14.47Cochlear : -2%, AU$94.76Paladin Energy : -2%, AU$12.28Origin Energy : -2%, AU$12.44EVT : -2%, AU$12.44Tuas : -2%, AU$5.97Ramsay Health Care : -2%, AU$39.15Southern Cross Gold : -2%, AU$11.07","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","TLX.AU","BK7067","BK7503","ORG.AU","NXG.AU","SX2.AU","BK7042","BK7083","WTC.AU","BK7507","BK7509","BK7130","BK7007","EVT.AU","BK7104","BK7035","BK7113","BK7006","COH.AU","TUA.AU","PDN.AU","RHC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331928","title":"ASX Growth Leaders With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331928?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:08","pubTimestamp":1777230494,"startTime":"0","endTime":"0","summary":"As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AV1.AU","BK7096","BK7036","FRS.AU","BK7110","BK7095","EIQ.AU","SKS.AU","BK7508","BK7506","IMA.AU","BK7067","AMI.AU","TLX.AU","BK7113","TOR.AU","XAO.AU","TTT.AU","BK7016","BK7104","TLX","REG.AU","MAU.AU","BK4139","XKO.AU","BK7023","AR1.AU","SPL.AU","BK7501","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629584720","title":"How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2629584720","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629584720?lang=en_us&edition=fundamental","pubTime":"2026-04-24 19:05","pubTimestamp":1777028712,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced several milestones, including the first patient dosed in the pivotal Phase 3 IPAX BrIGHT trial of TLX101-Tx for recurrent glioblastoma and the upcoming presentation of Phase 3 safety data for its prostate cancer therapy TLX591-Tx at the 2026 ASCO Annual Meeting.\nIn parallel, Regeneron Pharmaceuticals and Telix entered a broad collaboration pairing Regeneron’s antibody portfolio with Telix’s radiopharmaceutical platform, potentially expanding Telix’s...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629183506","title":"Plus Therapeutics starts REYOBIQ manufacturing technology transfer with SpectronRx under MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2629183506","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629183506?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:33","pubTimestamp":1776943988,"startTime":"0","endTime":"0","summary":"Plus Therapeutics began manufacturing activities with SpectronRx under a previously executed master services agreement to support GMP pivotal-trial readiness for REYOBIQ.SpectronRx will serve as a second GMP manufacturing site alongside Radiomedix, with Rhenium-186 isotope supply sourced through Telix Pharmaceuticals.Technology transfer to SpectronRx covers REYOBIQ manufacturing process, Rhenium-186 processing, analytical methods.SpectronRx facility in Indiana will provide on-demand production for both Rhenium-186 and REYOBIQ in one site to streamline logistics.Plus is targeting completion of manufacturing scale-up for late-stage clinical supply needs in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL47wJfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","BK4139","PSTV","SG9999014005.SGD","TLX.AU","NDAQ","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","IE00BN0W2T93.GBP","BK7067","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629809008","title":"Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629809008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629809008?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:16","pubTimestamp":1776910582,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is \"substantially complete.\"After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX","BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629507036","title":"BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2629507036","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629507036?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:37","pubTimestamp":1776908256,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Announces Settlement Of $600M Convertible BondsApril 23  - Telix Pharmaceuticals Ltd TLX.AX:TELIX ANNOUNCES SETTLEMENT OF US$600M CONVERTIBLE BONDSNEW BONDS EXPECTED TO BE LISTED ON SGX-ST ON APRIL 23, 2026Further company coverage: TLX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4151CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629207191","title":"Telix Pharmaceuticals Ltd - Telix Announces Settlement of US$600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2629207191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629207191?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:42","pubTimestamp":1776901325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071917","title":"Telix Pharmaceuticals Ltd - New Bonds Expected to Be Listed on Sgx-St on April 23, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071917?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:42","pubTimestamp":1776901325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151CA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706821","title":"Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706821?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:49","pubTimestamp":1776804573,"startTime":"0","endTime":"0","summary":"Telix flagged preliminary safety and dosimetry findings from Part 1 of its ProstACT Global Phase 3 study as a late-breaking oral presentation at ASCO 2026.Data will be presented June 1, 2026, covering TLX591-Tx used with standard of care in PSMA-positive metastatic castration-resistant prostate cancer.Part 1 supports trial progression by evaluating tolerability, biodistribution, and radiation dose profile in a lead-in setting.ProstACT Global compares TLX591-Tx combined with standard of care versus standard of care alone, aiming to support broad adoption across major markets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLYQBMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","TLX.AU","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","BK7067","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629070229","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070229","media":"Simply Wall St.","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070229?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:10","pubTimestamp":1776737430,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh investor attention after Regeneron agreed to a US$40 million upfront payment to access its radiopharmaceutical platform, alongside Telix starting the pivotal Phase 3 IPAX BrIGHT trial in recurrent glioblastoma.\nSee our latest analysis for Telix Pharmaceuticals.\nAgainst this backdrop, Telix’s recent news is landing on a share price that has gained 15.76% over the past 30 days and 28.46% over 90 days, while the 1 year total shareholder return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703479","title":"Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703479","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629703479?lang=en_us&edition=fundamental","pubTime":"2026-04-21 09:55","pubTimestamp":1776736508,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  was the most shorted stock on the Australian Securities Exchange as of April 15 with 16.51% short positions, taking the place of Domino's Pizza Enterprises , according to data from the Australian Securities & Investments Commission.Domino's Pizza is now the second most shorted stock with 15.44% short positions, data showed.Telix Pharmaceuticals' shares fell 2% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1548497426.USD","LU1861219969.SGD","LU2360107325.USD","ON","LU0124384867.USD","BK4139","LU2357305700.SGD","BK7137","BK4141","BK4107","LU0724618433.USD","BK4588","LU1861215975.USD","BK4512","LU1978683503.SGD","LU1854103824.USD","DMP.AU","LU1861214812.USD","ASIC","BK4585","LU1861220033.SGD","LU1854104046.USD","BK7067","LU2298322129.HKD","LU0348723411.USD","TLX","BK4605","LU1720051017.SGD","LU1720051108.HKD","IE00BZ199S13.USD","IE00BD6J9T35.USD","IE00BFMHRM44.USD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628678712","title":"NuWays reiterates Eckert & Ziegler buy rating, sets EUR 23 target price","url":"https://stock-news.laohu8.com/highlight/detail?id=2628678712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628678712?lang=en_us&edition=fundamental","pubTime":"2026-04-20 15:01","pubTimestamp":1776668483,"startTime":"0","endTime":"0","summary":"NuWays reiterated a BUY rating on Eckert & Ziegler with a 12-month target price of EUR 23.Report flagged May 12 as date for Q1 2026 results, forecasting sales of EUR 72.5 million.NuWays projected adjusted EBIT of EUR 16 million, implying a 22.1% margin.Medical segment expected to drive growth, with Q1 segment sales seen up 13% to EUR 39 million.Analyst expects no license income in Q1, with remaining Telix-related license revenue of EUR 5.6 million likely later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL8bg36M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628606227","title":"Telix Pharmaceuticals Says JPMorgan Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2628606227","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628606227?lang=en_us&edition=fundamental","pubTime":"2026-04-17 13:35","pubTimestamp":1776404146,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said JPMorgan Chase & Co. and its affiliates have increased their stake in the company on Tuesday to 11.5% or 39 million shares from 7.7% or 26.1 million shares, according to a Friday Australian bourse filing.The company's shares fell past 2% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","LU0345770993.USD","IE0034235303.USD","JPMO","LU2264538146.SGD","TLX","LU2213496289.HKD","LU2023250504.SGD","IE00BJTD4N35.SGD","LU0417517546.SGD","IE00BYXW3230.USD","LU2756315318.SGD","LU0265550359.USD","LU2430703251.USD","BK7067","IE00BWXC8680.SGD","LU0215105999.USD","LU0859254822.USD","LU1548497426.USD","LU1084165304.USD","IE00BDRTCR15.USD","JPO","LU0868494617.USD","LU0942090050.USD","LU1670628061.USD","LU1917777945.USD","BK4585","LU0964807845.USD","LU0211326839.USD","TLX.AU","LU2756315664.SGD","LU1116320901.HKD","LU2746668461.USD","LU0345769631.USD","LU2242649171.HKD","LU1720051017.SGD","LU2552382132.HKD","LU2023250843.SGD","LU0211328371.USD","LU0251132253.USD","LU1668664300.SGD","BK4550","LU2237443382.USD","LU0106261372.USD","BK4139","LU0310799852.SGD","LU1116320737.USD","LU0203345920.USD","LU0211327993.USD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627400631","title":"Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400631","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627400631?lang=en_us&edition=fundamental","pubTime":"2026-04-15 17:30","pubTimestamp":1776245418,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Wednesday it dosed the initial patient in a Phase 3 clinical trial evaluating its radiopharmaceutical therapy for recurrent glioblastoma, a type of brain cancer.The gl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123724179","title":"Stock Track | Telix Pharmaceuticals Plummets 5.11% Intraday Following $600 Million Convertible Bond Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1123724179","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123724179?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:03","pubTimestamp":1776211410,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares plummet 5.11% during intraday trading on Wednesday. The sharp decline came amid heightened market activity for the biopharmaceutical company.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420674","title":"Telix Doses First Patient in Phase 3 Ipax-Bright Trial of Tlx101-Tx for Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420674?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:04","pubTimestamp":1776207883,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA7D0BG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":198,"code":"91000000","status":"200"}]}}